Pterosin D-activated protein kinase A mitigates Alzheimer's disease in 5xFAD mice

Abstract

Background

Protein kinase A (PKA) is a key activator of cAMP response element-binding protein signaling; it plays a pivotal role in cognition, memory, and adult neurogenesis. Phosphodiesterase (PDE) inhibitors that indirectly activate PKA through cAMP are promising candidates for Alzheimer's disease (AD) therapeutics.

Objective

We examined whether pterosins bind directly to PKA as activators and enhance cognition and memory.

Methods

We investigated PKA phosphorylation and performed in silico docking analysis using the cAMP-binding domains (CBD1, CBD2) of bovine PKA. Our focus was on exploring the effects of oral pterosin D on learning and memory in a 5xFAD mouse model of AD.

Results

We demonstrated that C3-hydroxylated pterosins directly activated PKA in neuronal cells but not in astrocytes and did not affect intracellular cAMP levels or inhibit PDE. In silico modeling implied that C3-hydroxylated pterosins fitted the CBD of PKA. Pterosins enhanced long-term potentiation mossy fiber-CA1 in the mouse hippocampus without affecting normal synaptic transmission. Pterosins more potently accelerate neuronal proliferation and neurite outgrowth in primary mouse cortical neurons than dibutyryl-cAMP does. Pterosin D significantly restored cognition and memory in 5xFAD mice on the Morris water maze.

Conclusions

C3-hydroxylated pterosins, as activators of PKA, have substantial potential as disease-modifying/-slowing therapeutic agent for AD.

Keywords

Alzheimer's disease cognition long-term potentiation memory neurite outgrowth protein kinase A activation pterosin

Get full access to this article

View all access options for this article.

References

Saez-Atienzar

Masliah

. Cellular senescence and Alzheimer disease: the egg and the chicken scenario. Nat Rev Neurosci 2020; 21: 433–444.

Saura

Valero

. The role of CREB signaling in Alzheimer’s disease and other cognitive disorders. Rev Neurosci 2011; 22: 153–169.

Hardy

Selkoe

. The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 2002; 297: 353–356.

Giacobini

. Cholinergic function and Alzheimer’s disease. Int J Geriatr Psychiatry 2003; 18: S1–S5.

Buée

Bussière

Buée-Scherrer

, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33: 95–130.

Praticò

. Evidence of oxidative stress in Alzheimer’s disease brain and anti-oxidant therapy. Ann N Y Acad Sci 2008; 1147: 70–78.

Block

Zecca

Hong

. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57–69.

Byrne

Vonderach

Ferries

, et al. cAMP-dependent protein kinase (PKA) complexes probed by complementary differential scanning fluorimetry and ion mobility-mass spectrometry. Biochem J 2016; 473: 3159–3175.

Silva

Kogan

Frankland

, et al. CREB And memory. Annu Rev Neurosci 1998; 21: 127–148.

10.

Vincent

Castro

. Signaling: spatial regulation of axonal cAMP. Nat Chem Biol 2017; 13: 348–349.

11.

Ortega-Martínez

. A new perspective on the role of the CREB family of transcription factors in memory consolidation via adult hippocampal neurogenesis. Front Mol Neurosci 2015; 8: 46.

12.

Whitlock

Heynen

Shuler

, et al. Learning induces long-term potentiation in the hippocampus. Science 2006; 313: 1093–1097.

13.

Vitolo

Sant'Angelo

Costanzo

, et al. Amyloid β-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A 2002; 99: 13217–13221.

14.

Sanders

Rajagopal

. Phosphodiesterase inhibitors for Alzheimer’s disease: a systematic review of clinical trials and epidemiology with a mechanistic rationale. J Alzheimers Dis Rep 2020; 4: 185–215.

15.

Yiu

Rashid

Josselyn

. Increasing CREB function in the CA1 region of dorsal hippocampus rescues the spatial memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 2011; 36: 2169–2186.

16.

Sumi

Harada

. Mechanism underlying hippocampal long-term potentiation and depression based on competition between endocytosis and exocytosis of AMPA receptors. Sci Rep 2020; 10: 14711.

17.

Yang

Khom

Lee

, et al. A phosphodiesterase 4 (PDE4) inhibitor, amlexanox, reduces neuroinflammation and neuronal death after pilocarpine-induced seizure. Neurotherapeutics 2024; 21: e00357.

18.

Kerns

Fan

, et al. High throughput artiﬁcial membrane permeability assay for blood-brain barrier. Eur J Med Chem 2003; 38: 223–232.

19.

Tanabe

Kozawa

Iida

. cAMP/PKA enhances interleukin-1β-induced interleukin-6 synthesis through STAT3 in glial cells. Cell Signal 2016; 28: 19–24.

20.

Heckman

PRA

Blokland

Ramaekers

, et al. PDE And cognitive processing: beyond the memory domain. Neurobiol Learn Mem 2015; 119: 108–112.

21.

Lafon

Rahman

Bikson

, et al. Direct current stimulation alters neuronal input/output function. Brain Stimul 2017; 10: 36–45.

22.

Crivori

Cruciani

Carrupt

, et al. Predicting blood−brain barrier permeation from three-dimensional molecular structure. J Med Chem 2000; 43: 2204–2216.

23.

Bliss

Lomo

. Plasticity in a monosynaptic cortical pathway. J Physiol 1970; 207: 61P.

24.

Rioult-Pedotti

Friedman

Donoghue

. Learning-induced LTP in neocortex. Science 2000; 290: 533–536.

25.

Martin

Grimwood

Morris

. Synaptic plasticity and memory: an evaluation of the hypothesis. Annu Rev Neurosci 2000; 23: 649–711.

26.

Loy

Schofield

Turner

, et al. Genetics of dementia. Lancet 2014; 383: 828–840.

27.

Sun

Zhou

Yang

, et al. Analysis of 138 pathogenic variants in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase. Proc Natl Acad Sci U S A 2017; 114: E476–E485.

28.

Forner

Kawauchi

Balderrama-Gutierrez

, et al. Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer’s disease. Sci Data 2021; 8: 270.

29.

Sepúlveda

Hernández

Burgos

, et al. The cAMP/PKA pathway inhibits beta-amyloid peptide release from human platelets. Neurosci 2019; 397: 159–171.

30.

Greggio

Bubacco

Russo

. Cross-talk between LRRK2 and PKA: implication for Parkinson's disease. Biochem Soc Trans 2017; 45: 261–267.

31.

Dagda

Gusdon

Pien

, et al. Mitochondrially localized PKA reverses mitochondrial pathology and dysfunction in a cellular model of Parkinson's disease. Cell Death Differ 2011; 18: 1914–1923.

32.

Dagda

Das Banerjee

. Role of PKA in regulating mitochondrial function and neuronal development: implications to neurodegenerative diseases. Rev Neurosci 2015; 26: 359–370.

33.

Belmaker

Agam

. Major depressive disorder. N Engl J Med 2008; 358: 55–68.

34.

Wand

Levine

Zweifel

, et al. The cAMP–protein kinase A signal transduction pathway modulates ethanol consumption and sedative effects of ethanol. J Neurosci 2014; 21: 5297–5303.

35.

Dibner

Schibler

Albrecht

. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol 2010; 72: 517–549.

36.

Berrios

Newbern

, et al. An autism-linked mutation disables phosphorylation control of UBE3A. Cell 2011; 162: 795–807.

37.

Kitagishi

Minami

Nakanishi

, et al. Neuron membrane trafficking and protein kinases involved in autism and ADHD. Int J Mol Sci 2015; 16: 3095–3115.

38.

Mueller

Schoeberlein

Zhou

, et al. Preimplantation factor bolsters neuroprotection via modulating protein kinase A and protein kinase C signaling. Cell Death Differ 2015; 22: 2078–2086.

39.

Cogo

Tomkins

Vavouraki

, et al. Cytosolic sequestration of spatacsin by protein kinase A and 14-3-3 proteins. Neurobiol Dis 2022; 174: 105858.

40.

Lin

Chang

Chen

, et al. Regulation of feedback between protein kinase A and the proteasome system worsens Huntington's disease. Mol Cell Biol 2013; 33: 1073–1084.

41.

Bączyk

Alami

Delestrée

, et al. Synaptic restoration by cAMP/PKA drives activity-dependent neuroprotection to motoneurons in ALS. J Exp Med 2020; 217: e20191734.

42.

Kerkhof

LMC

van de Warrenburg

BPC

van Roon-Mom

WMC

, et al. Therapeutic strategies for spinocerebellar ataxia type 1. Biomol 2023; 13: 788.

43.

Korzus

. Rubinstein-Taybi syndrome and epigenetic alterations. Adv Exp Med Biol 2017; 978: 39–62.

44.

Widomska

De Witte

Buitelaar

, et al. Molecular landscape of Tourette’s disorder. Int J Mol Sci 2023; 24: 1428.

45.

Ruehr

Russell

Ferguson

, et al. Targeting of protein kinase A by muscle A kinase-anchoring protein (mAKAP) regulates phosphorylation and function of the skeletal muscle ryanodine receptor. J Biol Chem 2003; 278: 24831–24836.

46.

Layland

Solaro

Shah

. Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 2005; 66: 12–21.

47.

Potter

Baird

. Carcinogenic effects of ptaquiloside in bracken fern and related compounds. Br J Cancer 2000; 83: 914–920.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

29.01 MB